An observational study in Type 1 Diabetes, sponsored by Insulet Corporation. Recruiting at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Insulet Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Insulet Corporation.
Among the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation, this one is one of 2 that started in 2023, is one of 3 observational ones, and was the 10th registered.
3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →4 of the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation are open now, in 3 countries. Recruiting first, the newest first:
Insulet Corporation · Sites in New Zealand
Ages 2–70 · Healthy volunteers
Insulet Corporation · Sites in United States
Ages 14–75
Insulet Corporation · Sites in France
Ages 2+
By country, each count listing its studies:
Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 2 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 2,200 is above the median of 125 across 792 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 80 across the 11 interventional studies, 304 across the 3 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Insulet Corporation is the lead sponsor of 23 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
5 of the studies in Diabetes Mellitus, Type 1 by Insulet Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07593625Insulet CorporationEvaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D | 2026-12-31 |
| NCT07579702Insulet CorporationEfficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System | 2027-02-22 |
| NCT06144554Insulet CorporationPost Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes | 2027-06 |
| NCT07039942Insulet CorporationFrench Prospective Multicentric Study in Real World | 2027-07-30 |
| NCT07317102Insulet CorporationOmnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B) | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a decentralized observational clinical registry to collect real-world evidence related to the safety and effectiveness of the Omnipod 5 system in children and adults with Type 1 Diabetes.
This is a decentralized observational clinical registry to collect real-world evidence related to the safety and effectiveness of the Omnipod 5 system in children and adults with Type 1 Diabetes.
A minimum of 2,200 Type 1 participants will be recruited to ensure a minimum of 1,650 participants completing 12 months of follow-up. The minimum number of completed participants is as follows:
In addition to the enrollment targets above, a minimum of 1100 Omnipod-naïve users, 880 pump-naïve users, and 110 CGM-naïve users will be recruited.
Participants are expected to be followed for 12 months.
All new users for the Omnipod 5 System will be required to register with Insulet's Podder Central. Users already in Podder Central will be required to log into their account before logging into the Omnipod 5 Controller if transitioning to the Omnipod 5 System.
A minimum of 2,200 Type 1 participants will be recruited.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All new users for the Omnipod 5 System will be required to register with Insulet's Podder Central. Users already in Podder Central will be required to log into their account before logging into the Omnipod 5 Controller if transitioning to the Omnipod 5 System. As part of the onboarding process, users will be invited to participate in this registry.
Device: Omnipod 5
The Omnipod 5 System consists of a tubeless insulin Pod and the Omnipod® 5 App, installed on a designated Controller or compatible Android smartphone. The Omnipod 5 System works with the Dexcom G6® Continuous Glucose Monitoring System to continuously adapt and automatically deliver insulin according to personal needs. Every two weeks while on the Omnipod 5 system, participants will receive a push notification to complete assessments including any severe hypoglycemia or diabetic ketoacidosis events experienced since the prior assessment.
Incidence rate of severe hypoglycemia
Measures frequency of severe hypoglycemia
Time frame: From baseline to study completion, up to 12 months.
Incidence rate of DKA
Measures frequency of DKA
Time frame: From baseline to study completion, up to 12 months.
A1c at 3, 6, 9 and 12 months
Measures device effectiveness
Time frame: Comparing the change in A1c at baseline compared to at 3, 6, 9 and 12 months
Percentage of time < 54 mg/dL
Glucose metric from study continuous glucose monitoring system
Time frame: From baseline to study completion, up to 12 months
Percentage of time < 70 mg/dL
Glucose metric from study continuous glucose monitoring system
Time frame: From baseline to study completion, up to 12 months
Percentage of time > 180 mg/dL
Glucose metric from study continuous glucose monitoring system
Time frame: From baseline to study completion, up to 12 months
Percentage of time > 250 mg/dL
Glucose metric from study continuous glucose monitoring system
Time frame: From baseline to study completion, up to 12 months
Percentage of time in range 70-180 mg/dL
Glucose metric from study continuous glucose monitoring system
Time frame: From baseline to study completion, up to 12 months
Mean Glucose mg/dL
Glucose metric from study continuous glucose monitoring system
Time frame: From baseline to study completion, up to 12 months
Standard deviation of glucose mg/dL
measure of the range of glucose readings
Time frame: From baseline to study completion, about 12 months
Glucose management indicator %
MI tells you what your approximate A1C level is likely to be, based on the average glucose level from your CGM readings for 14 or more days.
Time frame: From baseline to study completion, up to 12 months
Percentage of participants achieving A1C < 7%
measurement of percentage of participants with A1c less than 7%
Time frame: From baseline to study completion, up to 12 months
Percentage of participants with time in range > 70%
measurement of percentage of participants with time in range \> 70%
Time frame: From baseline to study completion, up to12 months
Percentage of participants with time below range (<70mg/dL) of < 4%
measurement of percentage of participants with time below range (\<70mg/dL) of \< 4%
Time frame: From baseline to study completion, up to 12 months
Insulin Usage
Measure of insulin requirements
Time frame: From baseline to study completion, up to 12 months
Body Mass Index (BMI) or BMI z-score
Changes in body mass index
Time frame: at 6 months and at the end of registry participation, up to 12 months.
EQ-5D (inclusive of the Visual Analogue Scale (VAS))
Questionaire
Time frame: at baseline, at 6 months and at the end of registry participation, up to 12 months.
Insulin Delivery Systems: Perceptions, Ideas, Reflections, and Expectations (INSPIRE)
Questionaire
Time frame: at baseline, at 6 months and at the end of registry participation, up to 12 months
System Usability Scale (SUS)
Questionnaire
Time frame: at baseline, at 6 months and at the end of registry participation, up to 12 months
Incidence rate of prolonged hyperglycemia (events per person months) during usage of Activity Feature
Measuring rate of prolonged high sugar while in activity feature
Time frame: From baseline to study completion, up to 12 months
Incidence rate of prolonged hyperglycemia (events per person months)
Measuring the occurrence of prolonged hyperglycemia
Time frame: From baseline to study completion, up to 12 months
Incidence rate of prolonged hyperglycemia (events per person months) during usage of a Target Glucose of 140 mg/dL or 150 mg/dL
Measuring the occurrence of prolonged hyperglycemia while at a set target glucose of 140mg/dL or 150mg/dL
Time frame: From baseline to study completion, up to 12 months
Glucose Outcomes during the 4-hour post-bolus period using the SmartBolus Calculator: o Percentage of time < 54 mg/dL o Percentage of time in range 70-180 mg/dL
Glucose metric from study CGM
Time frame: From baseline to study completion, up to 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Jun 2027, 45 months after the start.
Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 45 months is above that.
Counting every sponsor, half of 299 studies reached it within 30 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.